NeuroVive receives positive FDA feedback on its NeuroSTAT TBI development plan
Lund, Sweden, 6 September 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced positive U.S. Food and Drug Administration (FDA) feedback on its NeuroSTAT clinical development plan for the treatment of moderate to severe Traumatic Brain Injury (TBI) at a pre-IND (Investigational New Drug) meeting. The main feedback requested was on the design of the planned NeuroSTAT Phase II proof of concept TBI study.The FDA Formal Advice feedback supports the novel design proposed for the planned Phase IIstudy. The design includes, as an important endpoint, advanced